Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.53 |
| ▸ | CA1 | P00915 | 11/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA7 | P43166 | 5/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021413 | 0.85 | CA2 (0.52) | CA2CA1CA12CA9CA7 | |
| SCHEMBL29328168 | 0.84 | TAAR1 (0.52) | CA2CA1CA12CA9CA7 | |
| SCHEMBL18719479 | 0.84 | CA2 (0.53) | CA2CA1CA12CA9CA7 | |
| SCHEMBL10181733 | 0.83 | NPC1 (0.46) | SMN1; SMN2TSHRNPC1MAPTRAB9A | |
| SCHEMBL25516414 | 0.82 | KIF11 (0.52) | CA2CA1CA12CA9CA7 | |
| SCHEMBL12481467 | 0.82 | CA2 (0.52) | CA2CA1CA12CA9CA7 | |
| SCHEMBL10180558 | 0.82 | PSIP1 (0.50) | CA2CA1SMN1; SMN2NPC1MAPT | |
| SCHEMBL10181070 | 0.82 | ENPP2 (0.45) | KIF11SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL13953719 | 0.81 | CA2 (0.50) | CA2CA1CA12CA9CA7 | |
| SCHEMBL4733508 | 0.80 | LMNA (0.45) | SMN1; SMN2TSHRNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150677-A1 | ACTIVE-RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION | 富士フイルム株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-05-02 | — | — | US | disclosed |
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-9760003-B2 | Pattern forming method and actinic-ray- or radiation-sensitive resin composition | FUJIFILM CORPORATION (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9709892-B2 | Actinic-ray- or radiation-sensitive resin composition and method of forming pattern using the same | FUJIFILM CORPORATION (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-9551935-B2 | Pattern forming method and resist composition | FUJIFILM CORPORATION (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9411230-B2 | Pattern forming method, electron beam-sensitive or extreme ultraviolet-sensitive composition, resist film, method for manufacturing electronic device using the same, and electronic device | FUJIFILM CORPORATION (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20160122577-A1 | HARD COAT FILM, POLARIZING PLATE, AND TOUCH PANEL DISPLAY | FUJIFILM CORPORATION (JP) | 2016-05-05 | — | — | US | disclosed |
| US-7776904-B2 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-7776904-B2 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
| EP-1917242-B1 | AZABICYCLO [3.1.0]HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-1917242-B1 | AZABICYCLO [3.1.0]HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-1917242-A1 | AZABICYCLO [3.1.0]HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022935-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007022935-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | CA2 2004/4885CA1 1130/4885CA12 2345/4885 |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, HTR3C | CA2 2753/4885CA1 2166/4885CA12 3140/4885 |
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | AXL, TYRO3, MERTK | CA2 3432/4885CA1 4052/4885CA12 4436/4885 |
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | CA2 4407/4885CA1 3493/4885CA12 3546/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CA2 3837/4885CA1 3827/4885CA12 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.